

### AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 58, line 30 and ending at page 59, line 6 with the following replacement paragraph:

Figure 7 illustrates the overview of the testis ACE structure. (a) Ribbon diagram of the molecule looking down on the active site. The molecule can be divided into 2 halves as domains I and II show in cyan and pink respectively. The active site zinc ion and the lisinopril molecule are shown in yellow. The two chloride ions are shown as black spheres. (b) The molecular surface representation showing the active site groove. (c) The structure-sequence relationship in ACE (SEQ ID NO: 2). The secondary structure elements (domain I-cyan; domain II-pink) follow the same colour code as in (a). The important residues which are involved in binding are marked-zinc ligands (yellow), chloride binding residues (C11-light green, C12-dark green), lisinopril binding residues (cyan) and glycosylation sites (open boxes).

Please replace the paragraph beginning at page 62, line 7 and ending at page 62, line 18 with the following replacement paragraph:

g1-F (40-mer): 5'-gaggccaattggaactacaacaccagatcaccacagag3' (SEQ ID NO: 3)

g2-F (36-mer): 5'-atgcaaatagccagcacacccttaagtacggcacc-3' (SEQ ID NO: 4)

g3-F (40-mer): 5'-gaagtttgatgttaaccagttgcagcagaccactatcaag-3' (SEQ ID NO: 5)

g4-F (30-mer): 5'-gtgtgccaccgcgaaggtagctgcctgcag-3' (SEQ ID NO: 6)

g5-F (36-mer): 5'-ccgtgcctcctgaattctggcagaagtcgatgctgg-3' (SEQ ID NO: 7)

g6-F (36-mer): 5'-acgggccagccccagatgagcgcttcggcc-3' (SEQ ID NO: 8)

Reverse primers are complementary to the forward primers:

g1-R (40-mer): 5'-ctctgtggtgatctgggtgttagttccaattggcctcg-3' (SEQ ID NO: 9)

g2-R (36-mer): 5'-gggtgccgtacttaagggtgtgctgggctatttgcac-3' (SEQ ID NO: 10)

g3-R (40-mer): 5'-cttgatagtggctgctgcaactggtaacatcaaacttc-3' (SEQ ID NO: 11)

Application No. 10/527,707  
Amendment dated September 12, 2005  
First Preliminary Amendment

Docket No.: 30699/41065

**AMENDMENTS TO THE SEQUENCE LISTING**

Please insert the attached Sequence Listing (pages 1 – 8) to the above-referenced application.